Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series. Arroyo-Andres J, Agud-Dios M, Rubio-Muniz CA, Postigo C, et al. Int J Dermatol 2023 Dec 13. doi: 10.1111/ijd.16979.

Read + Share

Amedeo Smart

Independent Medical Education

Arroyo-Andres J, Agud-Dios M, Rubio-Muniz CA, Postigo C, et al. Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series. Int J Dermatol 2023 Dec 13. doi: 10.1111/ijd.16979.
PMID: 38093412